US10131667, Example 65;11-(2,6-difluoro-3,5-dimethoxyphenyl)-13-[(3-fluorophenyl)methyl]-5,7,11,13-tetrazatricyclo[7.4.0.02,6]trideca-1,6,8-triene-4,12-dione
CAS
1513857-16-3
化学式
C24H19F3N4O4
mdl
——
分子量
484.434
InChiKey
FJIVZCVOYOZHPF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
物化性质
计算性质
ADMET
安全信息
SDS
制备方法与用途
上下游信息
反应信息
文献信息
表征谱图
同类化合物
相关功能分类
相关结构分类
计算性质
辛醇/水分配系数(LogP):
2.3
重原子数:
35
可旋转键数:
5
环数:
5.0
sp3杂化的碳原子比例:
0.21
拓扑面积:
84
氢给体数:
1
氢受体数:
8
文献信息
SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
申请人:Incyte Corporation
公开号:US20170137424A1
公开(公告)日:2017-05-18
The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
Substituted tricyclic compounds as FGFR inhibitors
申请人:Incyte Corporation
公开号:US11053246B2
公开(公告)日:2021-07-06
The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
[EN] SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS<br/>[FR] COMPOSÉS TRICYCLIQUES SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE FGFR
申请人:INCYTE CORP
公开号:WO2014007951A2
公开(公告)日:2014-01-09
The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.